Autopsy report · NCT00983346

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

“Lab Staff that was required left the institution, therefore accrual closed prematurely”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 11 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

Cancer; Myeloma; Multiple Myeloma

Interventions

Bortezomib

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
  “Closed prematurely because the accrual was not achieved” (68% match in meaning)
• Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
  “Lack of accrual. PI left the institution” (66% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (65% match in meaning)
• Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
  “accrual was slow and sporadic so the study was closed” (64% match in meaning)
• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
  “Study was terminated due to lack of accrual” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.